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Abstract
Background: We previously observed that a radiotherapy-induced biochemical response in plasma was associated
with favourable outcome in head and neck squamous carcinoma cancer (HNSCC) patients. The aim of the present
study was to compare stress associated blood cell gene expression between two sub-groups of HNSCC patients
with different biochemical responses to radiotherapy.
Methods: Out of 87 patients (histologically verified), 10 biochemical ‘responders’ having a high relative increase in
plasma oxidative damage and a concomitant decrease in plasma antioxidants during radiotherapy and
10 ‘poor-responders’ were selected for gene-expression analysis and compared using gene set enrichment analysis.
Results: There was a significant induction of stress-relevant gene-sets in the responders following radiotherapy
compared to the poor-responders. The relevance of the involvement of similar stress associated gene expression for
HNSCC cancer and radioresistance was verified using two publicly available data sets of 42 HNSCC cases and
14 controls (GEO GSE6791), and radiation resistant and radiation sensitive HNSCC xenografts (E-GEOD-9716).
Conclusions: Radiotherapy induces a systemic stress response, as revealed by induction of stress relevant gene
expression in blood cells, which is associated to favourable outcome in a cohort of 87 HNSCC patients. Whether
these changes in gene expression reflects a systemic effect or are biomarkers of the tumour micro-environmental
status needs further study.
Trial registration: Raw data are available at ArrayExpress under accession number E-MEXP-2460.
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Background
The strategy of cancer radiotherapy (RT) involves the
eradication of cancer cells while sparing the surrounding
normal tissues. When cells are exposed to RT, stress
responses leading to the apoptotic cell death of tumour
cells are activated. The global tissue responses to RT
seem to be directed towards limiting damage, inducing
repair processes and restoring tissue homeostasis [1].
However, it is not known how the systemic response to
RT affects outcome.
The main risk factors associated with head and neck
squamous carcinoma cancer (HNSCC) are related to an
unhealthy lifestyle accompanied by alcohol and tobacco
use and low daily intake of fruits and vegetables [2,3].
According to the second expert panel report on food and
cancer prevention, non-starchy vegetables, fruits, and also
foods containing carotenoids probably protect against the
development of HNSCC [4]. We have previously observed
in a pilot study that high levels of both post-RT carote-
noids (biomarkers of fruit and vegetable intake) and en-
dogenous plasma antioxidants (glutathione [GSH]) show a
significant positive association with survival in patients
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with HNSCC [5,6]. In a larger follow-up study with 87
HNSCC patients and 100 healthy controls the effect of RT
on a variety of biomarkers were assessed and pre-RT levels
were compared with those in healthy controls [7]. Dietary
antioxidants (carotenoids, tocopherols and ascorbic acid)
and ferric reducing antioxidant power (FRAP) were lower
in HNSCC patients compared to controls and dietary anti-
oxidants decreased during RT. High pre-RT plasma anti-
oxidant levels were positively associated with survival.
During RT, decrease in ferric reducing power analysis
(FRAP) was positively associated to survival. Similarly,
high RT-induced increase in total hydryoperoxides (deriva-
tives of reactive oxygen species [DROM]; plasma bio-
marker of oxidative stress) was also positively associated
with survival [7].
Based on these results we selected one subgroup of
patients that had responded to RT with a high increase in
DROM and a concomitant decrease in FRAP (responders)
and a subgroup of patients with the inverse combination
of responses (poor-responders). Changes in gene expres-
sion is a major component of stress responses [8]. The pri-
mary aim of our study was therefore to compare these
subgroups to identify differential blood cell gene expres-
sion relevant for stress and defence responses, such as
DNA repair and apoptosis, both before (pre-RT) and dur-
ing RT treatment. Such responses have previously been
reported to be implicated in tumour development and
radiation resistance in human cancers [9]. The relevance
of the involvement of similar stress-associated gene-
expression for HNSCC cancer and radio-resistance was
therefore verified using two independent publicly available
gene expression datasets.
Methods
Study population, sample preparation and analysis
This study reports the results of a subgroup of a larger
study of HNSCC patients recruited from the Division of
Cancer Medicine and Radiotherapy, Norwegian Radium
Hospital, Rikshospitalet University Hospital in the period
from May 2003 to May 2006 [7]. All the patients gave
their written informed consent and the study was
approved by the Regional Committee for Medical Re-
search Ethics. The patients received either post-operative
RT or RT alone for a period of 5–7 weeks. Radiation
doses ranged from 50 Gy to 70 Gy. The inclusion criteria
and patient characteristics as well as methods for sample
preparation and plasma biomarker analyses are described
by Sakhi et al. [7].
Samples for whole blood RNA isolation were obtained
before and after RT using PAXgene Blood RNA Tubes
(QIAGEN, Cat. No. 762115). PAX tubes were stored for
3 days at 4°C before RNA isolation and maintained at
-80°C until microarray analysis.
RNA isolation and microarray
Whole blood RNA was isolated according to the method
detailed in the PAX kit handbook including the optional
on-column DNase digestion. All samples (n= 2x20) had
good RNA integrity as judged by a Bioanalyzer and suffi-
cient yield (>5 μg RNA). Affymetrix, one-cycle gene ex-
pression protocol was performed including the globin
transcription reduction (GeneChipWGlobin-Reduction:
Affymetrix) step. All reagents were purchased from
Affymetrix.
Fragmented and biotinylated cRNA was hybridised to
the Affymetrix Human Genome U133 Plus 2.0 arrays
according to Affymetrix protocols. Scanning of arrays and
image analysis were performed using GeneChip W Scanner
3000 7 G and Operating Software 1.4 from Affymetrix.
Affymetrix HG-U133 microarray data for the radioresis-
tant and radiosensitive human tumour xenografts and the
data set of 42 head and neck squamous cell carcinoma cases
and 14 controls were downloaded from Array-Express,
(accession number E-GEOD-9716 and GEO, GSE6791
respectively) where the description of RNA isolation,
hybridization and the labelling protocol is registered. The
following raw data files were used from E-GEOD-9716:
GSM245389, GSM245390, GSM245391, GSM245395,
GSM245396 and GSM245397. Results using this dataset
have been published by Khodarev et al. [10].
Data analysis
The MADMAX quality control (QC) pipeline (https://
madmax.bioinformatics.nl) was applied separately for the
clinical trial data and the human tumour xenograft data
to assess array quality and for robust multiarray average
(RMA)-normalisation. Two arrays from the clinical trial
failed QC criteria and were thus discarded. Baseline
comparisons in both the clinical trial and xenografts
were performed on log-transformed data (base 2).
Changes in gene expression during RT were obtained by
calculating log2 ratios between the before and after RT
intensities for every gene after RMA normalisation. The
groups were then compared with regard to this ratio.
Probe set annotation was updated via the NetAffx on the
Affymetrix website. The annotation file was last updated
on March 12th 2009. MIAME standards [11] were fol-
lowed in the analysis and storage of data. The raw data
are available at ArrayExpress by accession number
E-MEXP-2460 http://www.ebi.ac.uk/microarray-as/ae/.
Identification of significantly differentially expressed
genes at baseline and during RT
BAMarrayTM, a Bayesian ANOVA method for the ana-
lysis of microarray data that adjusts for multiple testing,
was used to identify differentially regulated gene tran-
scripts [12].
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Gene set enrichment analysis (GSEA)
Gene set enrichment analysis GSEA [13] was used to test
whether groups of genes involved in stress and defence
processes were differentially expressed pre-RT or differ-
entially changed during RT by comparing the ‘respon-
ders’ with the ‘poor-responders’ using J-express (http://
www.molmine.com). Gene set collections associated with
stress functions were obtained using a gene set browser
(Molecular Signatures Database v3.0) on the Broad insti-
tute website (http://www.broad.mit.edu/gsea/), as previ-
ously described [14] using the keywords such as
‘apoptosis’, ‘hypoxi*’ and others. The large, predefined gene
set collection; C3 (TFT), was also tested. In C3 (TFT) the
genes are grouped if they share a transcription factor
binding site (http://www.broad.mit.edu/gsea/). FDR q-
values < 5% was considered statistically significant.
Data analysis of biomarkers
SPSS (version 14.0) was employed to compare the pre-
RT levels and changes in FRAP, DROM, ascorbic acid,
tocopherols and the carotenoids. All comparisons were
performed using the Mann–Whitney (MW) test consid-
ering P-values < 0.05 as being statistically significant. For
clinical outcome overall survival was calculated from the
start of RT until death by any cause or last follow-up
examination. Progression-free survival was calculated
from the start of RT until relapse of last follow-up exam-
ination. The number of survivors after 3 years was com-
pared between the groups using the Fisher exact test.
The survival distributions of the two groups were com-
pared using the Log Rank test. Due to different practical
limitations, appropriate sample collection was not pos-
sible for every analysis in all patients and controls. Thus,
the numbers of samples were 15 for Glutathione disul-
fide (GSSG) and redox potential and 19 for total and
reduced glutathione (GSH).
Principal component analysis (PCA) was used to sum-
marise the main differences between the individuals
using the Unscrambler Version 9.8 (http://www.camo.
com). Detailed description of the analysis and how to in-
terpret the results can be found in online Additional file
1. The PCA figures were optimized (colors, fonts) using
Adobe illustrator CS2.
Results
Patient characteristics
Out of the 87 patients with histologically verified
HNSCC recruited in the present study, 10 biochemical
‘responders ’ and 10 ‘poor-responders’ were selected for
gene expression analysis (Figure 1) according to the fol-
lowing inclusion criteria. Among the patients with a high
(above median) negative change in plasma FRAP and a
high positive change in DROM during RT, 10 samples
were assigned to the responders group. Among the
patients with low negative change in plasma FRAP and a
low positive change in DROM during RT, 10 samples
were assigned to the ‘poor-responders’ group.
The ‘responders’ were compared with the ‘poor
responders’ with regard to baseline characteristics as
summarised in Table 1. There were no statistically sig-
nificant differences in baseline characteristics between
the two groups except there were differences in out-
come which was expected owing to the selection
criteria’s.
Effect of radiotherapy on whole blood stress associated
gene-expression
GSEA [13] was used to test whether gene sets associated
to stress responses were differentially changed during RT
in the ‘responders’ compared with the ‘poor responders’.
The stress associated gene sets were, in general, signifi-
cantly upregulated in the ‘responders’ relative to the
‘poor-responders’ (Table 2). These results indicate that
the group with the best prognosis had a significantly
higher induced stress-associated gene expression in re-
sponse to RT. Lists of the gene sets that were differen-
tially changed in ‘responders’ and ‘poor-responders’ can
be explored in Additional file 2: Table S2 and Additional
file 3: Table S3. used to test if gene sets associated with
stress responses were differentially expressed at pre-RT in
the 'responders' and ‘poor responders’. Table 2 lists
Assessedfor eligibility (n=87)
Excluded (n=7)
Previous history of cancer
Start of radio therapy (n=80)
Blood sampling
Al
lo
ca
tio
n
Ba
se
lin
e
Excluded (n=2)
Did not complete RT
Lost to follow-up (n=18)
End of radio therapy (n=60)
Blood sampling
Fo
llo
w
-u
p
t=
5-
7 
w
ee
ks
Plasma biomarkers:
Oxidativestress
Antioxidants
GSH related parameters
Blood sample analysis
Baseline and follow-up
Responders
(n=10)
Poor responders
(n=10)
PCA analysis PCA analysis
Excluded(n=1)
FailedQC-criteria
Sa
m
pl
e 
an
al
ys
is 
ba
se
lin
e 
an
d 
fo
llo
w-
up
Gene expression (n=9)
Excluded (n=1)
Failed QC criteria
Gene expression (n=9)
Figure 1 CONSORT (Consolidated Standards Of Reporting
Trials) diagram detailing the study. ‘Responders’: high relative
increase in DROM and concomitant decrease in FRAP in response to
RT. ‘Poor responders’: low relative increase or decrease in DROM and
concomitant low decrease or increase in FRAP in response to RT.
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the number of gene sets from each of the tested gene set
collections that were significantly different between the
groups’ pre-RT and the number of gene sets differentially
changed during RT (FDR<5%). In the ‘poor-responders’
a substantial amount of ‘stress’ gene sets were signifi-
cantly higher expressed at pre-RT when compared to
the‘ responders’ (FDR<5%). A list of the differentially
expressed gene sets between the ‘responders’ and ‘poor-
responders’ at pre-RT can be viewed in Additional file 4:
Table S4 and Additional file 5: Table S5.
Most of the gene sets that were higher expressed pre-
RT in the ‘poor-responders’ when compared to ‘respon-
ders’ were also found in the list of gene sets that were
induced significantly in the ‘responders’ when compared
to ‘poor-responders’ (FDR<5%). However, the number of
stress-associated gene-sets significantly induced in the‘
responders’ during RT was however much higher than the
number of gene-sets that were higher expressed at pre-RT
in the ‘non-responders’.
Furthermore we observed 4 significantly upregulated
C3TFT gene sets in the ‘responders’ group as compared to
the ‘poor-responders’ (FDR<5%). Two of the up-regulated
gene sets had regulatory motifs for unknown transcription
factors and 2 gene sets have motifs for the known
transcription factors CCAAT/enhancer binding protein
(CEBPB) and nuclear respiratory factor 2 (Additional file 2:
Table S2). Both transcription factors are involved in stress
and defence responses [15,16].
Relevance of stress associated gene expression for
radio-resistance
GSEA on a publicly available data set of radiation
resistant versus radiation sensitive HNSCC xenografts
(E-GEOD-9716) revealed that the radioresistant
tumour-xenografts had a higher basal expression of
stress related gene sets (GSEA, FDR < 5%) as compared
with the radio-sensitive xenografts (Table 3). All C3TFT
gene-sets that were higher expressed in the radioresis-
tant xenografts, were associated with interferon signal-
ling. Lists of the regulated gene sets can be explored in
online Additional file 6: Tables S6 and Additional file 7:
Table S7.
Relevance of stress associated gene expression for HNSCC
GSEA on a publicly available data set of 42 head and
neck squamous cell carcinoma cases and 14 controls
(GEO, GSE6791), revealed that HNSCC tumour tissue
had a higher basal expression of stress related gene sets
(GSEA, FDR < 5%) compared to normal endothelial cells
from healthy controls (Table 3). The C3TFT gene-sets
Table 1 Baseline charachteristics of the responders and the poor responders
Poor responders Responders p
BMI median (25%, 75% percentiles) 22 (21,27) 25 (23,29) 0.32
AGE (years, median (25%, 75% percentiles)) 61 (55,64) 59 (55,76) 0.91
Gender Men 9 10
Women 1 0 1.00}
Localisation larynx 1 5 0.18}
hypopharynx 3 0
oral cavity 4 3
oropharynx 2 2
Treatment RT 7 7 1.00}
Surgery and RT 3 3
Stage I 0 1 0.34}
II 1 3
III 1 2
IV 8 4
Smoking status Non smokers and former smokers 5 7 0.65}
Smokers 5 3
Survival (3 Year) Median (months) (25%, 75% percentiles) 18 (11,25) 30 (19,40) <0.01
Overall survivors (n) 4 10 0.01}
Median time to relapse, (months) (25%, 75% percentiles) 6 (5,21) 26 (16,34) <0.01
Progression-free survivors (n) 2 8 0.02}
BMI and age were compared between the groups using the Mann–Whitney test. Median values are given with interquantile range in brackets. Gender,
localization, treatment, stage, smoking status, number of overall survors and number of progression free survivors were compared using Fisher’s exact test(}).
Survival was compared using the log-rank test.
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that were more highlyexpressed in the tumour tissue had
common regulatory motives for various E2Fs, NRF2,
ARNT, NRF1, MYC and YY1. Lists of the regulated gene
sets can be explored in online Additional file 8: Table S8
and Additional file 9: Table S9.
Identification of significantly differentially expressed
genes before RT and during RT comparing ‘responders’
with ‘poor-responders’
Another statistical method, BAM arrayTM [12], was used
to identify significantly differentially expressed genes
Table 2 Summary of GSEA analysis comparing whole blood gene expression profiles of poor-responders (PR) to
responders (R) with regard to pre-RT gene expression levels and response to RT
Stress and defence relevant gene
set database (keyword)
Number of gene sets in collection HNSCC patients whole blood
HG-U133-plus2 Baseline expression pre-RT Change during RT
PR>R R>PR PR>R R>PR
Apoptosis 273 29 0 0 91
Cell and cycle 311 38 1 0 85
Cytokine* 239 41 0 0 89
Hypoxi* 63 5 0 0 25
Antioxidant* 10 8 0 0 4
Immune* and response 116 10 0 0 37
Stress and response 59 5 0 0 11
DNA and repair 80 12 0 0 13
Cancer 699 75 1 4 152
Tox* 136 23 0 1 49
C3 TFT 583 18 11 0 4
The number of stress and defence-relevant gene sets that were higher expressed in one group compared to the other are given for each gene set collection. FDR
(false discovery rate) < 5%.
Affymetrix HG-U133-plus2 chips were used to analyze the whole blood RNA. A gene set browser provided by Broad institute at www.broad.mit.edu/gsea/ was
used to obtain the stress-associated gene set collections. Detailed information regarding the regulated gene sets is given in online Additional files 2-5. *indicates
that truncated search keywords were used to create the gene set collections. C3TFT is a pre-defined gene set collections.
Table 3 Summary of GSEA analysis comparing radioresistant (RR) with radiosensitive (RS) HNSCC xenografts in nude
mice and HNSCC tumour tissue versus normal epithelial cells
Stress and defence relevant gene
set database (keyword)
Number of gene sets in collection HNSCC tumour cell
xenografts (GEOD-9716)
Baseline pre-RT
HNSCC tumour versus
controls (GEOGSE6791)
Baseline pre-RT
HG-U133-plus2 HG-U133A RR> RS RS>RR HNSCC>ctr ctr>HNSCC
Apoptosis 271 272 30 1 163 1
Cell and cycle 308 309 63 1 200 2
Cytokine* 239 236 33 0 104 2
Hypoxi* 63 63 7 0 41 0
Antioxidant* 10 10 2 0 2 0
Immune* and response 114 114 23 0 55 1
Stress and response 59 58 6 0 0 0
DNA and repair 80 79 14 0 57 0
Cancer 699 687 103 14 373 9
Tox* 137 140 16 2 70 2
C3 TFT 582 587 5 2 83 1
The number of stress and defence-relevant gene sets that were more highly expressed in one group relative to the other is given for each gene set collection.
False discovery rate (FDR) <5%.
Affymetrix HG-U133A microarray chips were used in the GEOD-9716 dataset while Affymetrix HG-U133-plus2 chips were used in the GSE6791 dataset. A gene set
browser provided by the Broad institute at www.broad.mit.edu/gsea/ was used to obtain the stress-associated gene set collections. Detailed information regarding
the regulated gene sets is given in online Additional files 6-9. *indicates that truncated search keywords were used to create the gene set collections. C3TFT is a
pre-defined gene set collection.
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before and during RT. Pre-RT, 123 genes were signifi-
cantly higher expressed in the ‘poor responders’ as com-
pared to the ‘responders’ while 352 genes were more
highly expressed in the ‘responders’ (Additional file 10:
Table S10).
During the RT period 61 gene transcripts were signifi-
cantly induced in the ‘responders’ while 80 were higher
induced in the ‘poor-responders’ (Additional file 11:
Table S11). The median fold change for each significantly
changed gene was calculated, and box plots were
obtained to summarise the RT effects in ‘responders’ and
‘poor responders’ (Figure 2). The median fold change in
gene-expression was higher in the ‘responders’ than in
the ‘poor responders’. Among the gene transcripts sig-
nificantly induced in the ‘responders’ (heatmap, figure 2)
several have previously been reported in association to
RTnamely. CXCL16 and ADAM17 [17], JUNB [18],
NOTCH [19], HTATIP2 [20,21], BRI3 [22], SOD2 [23]
and MMP9 [24]. In addition eight histone variants of the
H2B and H2A family [25] were significantly induced in
the ‘responders’.
Plasma biomarkers
Pre-RT plasma biomarkers and changes in these biomar-
kers during RT are summarised in Additional file 12,
Table S12 presented as median values with the corre-
sponding 95%CI. Principal component analysis (PCA)
was used to summarise the main differences between
the groups with regard to plasma biomarkers and infor-
mation on staging of tumour. Principal component (PC)
1 and PC 2 separated the ‘responders’ from the ‘poor-
responders’ with regard to pre-RT biomarkers and RT-
induced changes (Additional file 1: Figure S1A-D).
The Additional file 1 includes a detailed description of
how the figures are interpreted and the results.
Additional file 1: Figure S1A, correlation loading plot,
shows that the pre-RT plasma carotenoids (lycopene,
zeaxanthin, lutein, α-carotene and β-carotene) and as-
corbic acid (AA) correlate, and are associated to the
‘responders’.
On the other hand pre-RT DROM shows an inverse
correlation to the carotenoids and is associated to the
‘poor-responders’. Thus the ‘responders’ had higher
plasma levels of antioxidants and a lower level of oxida-
tive stress biomarker (DROM) before RT than the ‘poor-
responders’. Tumour stage seems not to be important in
relation to the separation of those subgroups.
The correlation loading plot of Additional file 1:
Figure S1D shows that the RT-induced changes in antiox-
idants (carotenoids and ascorbic acid) are important for
PC1 and therefore explains the group effect. The changes
in plasma antioxidants are highly correlated and the nega-
tive change in plasma antioxidants, increased ratio of oxi-
dised vitamin C/ vitamin C and increased DROM are
associated with the ‘responders’. Thus the ‘responders’
had higher induced levels of oxidative stress biomarkers
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Figure 2 Box plot of the median fold-change in the genes that were significantly differentially changed between the ‘poor responders’
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’non-responders’ listing the genes in the most up-regulated clusters.
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(oxidised vitamin C/ vitamin C and DROM) during RT
than the ‘poor-responders’ while using more plasma
antioxidants.
Discussion
The cornerstone of RT for cancer treatment is the induc-
tion of the oxidative stress with the purpose of killing
the tumour while sparing the normal tissue. To our
knowledge, it remains unknown as to how the host re-
sponse (i.e. the systemic response) to treatment affects
the outcome. We found that induction of systemic stress
responses seems to be involved in the successful res-
ponse to radiation therapy in HNSCC patients.
The results of this study is based on comparison of
two sub-groups of a previously published study [7]. In
this study Sakhi et al. demonstrated that a decrease in
FRAP during RT was positively associated to survival
and that a high RT-induced increase in plasma bio-
marker of oxidative stress (DROM) was similarly posi-
tively associated with survival. Based on these results we
identified two subgroups of HNSCC patients with differ-
ent response-signatures to RT with regard to changes in
oxidative stress biomarkers (DROM), plasma antioxi-
dants (FRAP) and outcome. The patients who responded
to RT with a high increase in DROM and concomitant
decrease in FRAP (the ‘responders’) were compared with
the patients who responded with the inverse combin-
ation of these two parameters (the ‘poor responders’).
We identified different responses to RT with regard to
modulation of gene-expression in whole blood by means
of whole blood gene expression. The responders exhib-
ited a significantly higher induction of genes associated
with stress responses such as DNA repair, apoptosis, and
hypoxia and also genes relevant to immune response.
Furthermore, the responders had a higher consumption
of plasma antioxidants indicated by decreased plasma
carotenoids, vitamin C and FRAP.
We also found that the ‘poor-responders’ with the poor
outcome had a significantly higher pre-RT stress status
as revealed by their gene expression profiles and also
plasma biomarkers (DROM and ratio of oxidized/
reduced AA). The poor responders also had a signifi-
cantly lower levelof plasma carotenoids pre-RT. We have
previously suggested that a study designed to test
whether increased intake of fruit and vegetables before
start of RT can improve survival would be valuable [6,7].
The current observation that patients with a high pre-RT
stress associated gene expression also had lower levels of
fruit and vegetable biomarkers supports this suggestion.
Most likely, plant foods may not only protect against oxi-
dative stress and the subsequent oxidative damage due to
antioxidant abilities but also activate adaptive defence
mechanisms [14,26].
One may speculate that the observed systemic stress
responses measured in blood cells are biomarkers of
changes in host characteristics during RT and therefore
potentially linked to modifiable lifestyle factors as for
instance diet or antioxidant intake. Treatment response
in oncology is not only dependent of tumour character-
istics and the therapy given, but also by host factors
such as the tumour microenvironment (including fibro-
blasts, endothelial cells and immune cells) [27]. In
addition, oxidative stress status in the tumour micro-
environment is possibly important for tumour progres-
sion [28].
The lack of treatment response in the ‘poor-
responders’ might be related to a higher initial pre-RT
stress level. A high pre-RT stress level could indicate that
the stress resistance mechanisms in the poor responders
are chronically high and thereby prohibit an adequate re-
sponse to RT. Increased defence mechanisms in tumour
cells have been associated with RT resistance both
in vitro and in vivo. For example; it is known that radi-
ation sensitivity is related to the efficiency of DNA
double-strand break repair. Defects/loss of function
in genes involved in DNA repair can thus enhance
radiation sensitivity. Inhibition of other stress protec-
tive proteins, such as the Hsp90, also enhances the
radiosensitivity both in vitro and in HNSCC xenograft
models [29].
Interestingly we verified that a similar stress relevant
gene expression pattern was significantly higher
expressed in tumour tissue compared to normal epithe-
lial cells in an independent publicly available data set of
HNSCC patients and normal controls.
It is also likely that the stress associated gene expres-
sion pattern is involved in RT resistance mechanisms.
Overexpression of stress relevant proteins such as GSH-
related enzymes and HIF1α in tumours has been shown
to participate in oncogenesis and in resistance to both
RT and chemotherapy [30-33]. Increased expression of
endogenous antioxidants has also been hypothesized to
be at least partially responsible for radiation-induced
adaptive responses [34-38]. We therefore tested whether
similar stress-associated gene-expression profile could be
relevant for RT resistance and used a publicly available
gene expression dataset of radioresistant and radiosensi-
tive xenografts for this purpose. Stress associated gene
expression was found to be relevant for radioresistance.
Our results are in line with the main findings from the
source publication for the xenograft dataset reporting
overexpression of IFN/STAT signalling in the radioresis-
tant xenografts [10]. Several of the gene sets that were
more highly expressed in the radioresistant xenografts
overlapped with those that were found to be differen-
tially expressed between the ‘responders’ and ‘poor
responders’ both before and during RT.
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Although there was no statistical difference in patients’
characteristics between the two groups, it can be argued
that the cohort is not well balanced with regard to site
of origin, staging and the low number of samples used.
In particular there were 3 hypopharynx cases in the poor
responders and 0 cases in the responders which poten-
tially could have an impact on the results since patients
with this tumour subsite have a worse outcome than
patients with other tumour localizations [39]. Conse-
quently we repeated the GSEA analysis on a dataset that
excluded the hypopharynx cases and showed that it did
not affect the results noteworthy (data not shown). In
addition, because stage of disease is associated with out-
come in HNSCC patients [7] we included tumour stage
as a parameter in the PCA analysis. Stage does not seem
to be important for the different biochemical response
to RT for the two groups in our study.
Although we have identified a biomarker panel that is
associated with outcome in patients that received RT we
cannot exclude that the changes that are induced during
RT period could have been induced or affected by other
stress factors during treatment (i.e. surgery, changes in nu-
trition, weight loss, fungal infections and other factors).
Conclusion
Although RT is a locoregional treatment modality, we
found systemic changes in the gene expression in non-
tumour cells i.e. blood cells. We demonstrated that the in-
duction of a systemic stress response, stress-relevant gene
expression in blood, seems to be important for successful
RT response and increased survival rates in HNSCC
patients. Furthermore we used two publicly available data
sets to validate that expression of stress associated genes
is relevant for RT resistance and that tumour cells from
HNSCC patients have a higher expression of these genes
as compared with cells from healthy subjects.
Whether the observed changes in blood cell gene ex-
pression reflects a systemic effect or are biomarkers of the
tumour microenvironment requires further elucidation.
Additional files
Additional file 1: Figure S1. Results from PCA analysis of plasma
biomarkers including a description of the method used.
Additional file 2: Table S2. List of gene sets that were more highly
induced in responders compared to poor-responders during RT.
Additional file 3: Table S3. List of gene sets that were more highly
induced in poor-responders compared to responders during RT.
Additional file 4: Table S4. List of gene sets that were more highly
expressed in the ‘responders’ compared to ‘poor-responders’ at pre-RT.
Additional file 5: Table S5. List of gene sets that were more highly
expressed in poor-responders than in responders at pre-RT.
Additional file 6: Table S6. List of gene sets that were more highly
expressed in the radioresistant xenograft samples than in the radiation
sensitive.
Additional file 7: Table S7. List of gene sets that were more highly
expressed in the radiosensitve xenograft samples than in the
radioresistant.
Additional file 8: Table S8. List of gene sets that were more highly
expressed in HNSCC tumour tissue than innormal endothelial cells from
controls.
Additional file 9: Table S9. List of gene sets that were more highly
expressed in normal endothelial cells from controls than in HNSCC
tumour tissue.
Additional file 10: Table S10. Genes significantly differentially
expressed in responders compared to poor-responders at pre-RT (BAM
array).
Additional file 11: Table S11. Genes significantly differentially induced
by RT in responders as compared with poor-responders.
Additional file 12: Table S12. Summary of the pre-RT plasma
biomarkers and RT induced changes in these biomarkers for responders
and poor responders.
Abbreviations
ADAM: A disintegrin and metalloprotease domain; ARNT: Aryl hydrocarbon
receptor nuclear translocator; BRI3: Brain protein I3; CEBPB: CCAAT/enhancer
binding protein; CXCL: Chemokine (C-X-C motif) ligand;
DHHA: Dehydroascorbic acid; DROM: Derivatives of reactive oxygen species;
FRAP: Ferric reducing power analysis; GSEA: Gene set enrichment analysis;
GSH: Glutathione; HNSCC: Head and neck squamous carcinoma cancer;
HTATIP2: HIV-1 Tat interactive protein; IFN: Interferone; MMP9: Matrix
metallopeptidase; MW: Mann–whitney; PCA: Principal component analysis;
RMA: Robust multiarray average; RT: Radiotherapy; SOD: Superoxide
dismutase; STAT: Signal-transducer and activator of transcription protein;
YY1: Yin-yang transcription factor 1.
Competing interests
The following authors declare no potential conflict of interest SKB, KMR, AKS,
MT, MH, JM, MCM, OKO and SS. RB has interests in Bioindex AS and Vitas
AS. Bioindex was established by Birkeland Innovation, the technology
transfer office at the University of Oslo while Vitas was established by Oslo
Innovation Center.
Authors' contributions
SKB, drafted the manuscript, participated in formulation of the hypothesis
and in the RNA-relevant work. She was responsible for the statistical analysis
together with MT and MH. KMR, participated in formulation of the
hypothesis, was responsible for sample collection and also responsible for
acquisition of patient data together with AKS. AKS, participated in
formulation of the hypothesis and was responsible for sample collection and
acquisition of patient data together with KMR. She performed the biomarker
analysis in patient samples. MT, participated in formulation of the hypothesis
and was responsible for the statistical analysis together with MT and SKB.
MH, was responsible for the statistical analysis together with SKB and MH.
J. Moskaug participated in formulation of the hypothesis and participated
in the RNA-relevant work. MCM participated in formulation of the hypothesis
and in the RNA-relevant work. OKO carried out the array hybridisation. SS
and RB participated in formulation of the hypothesis and revised the
manuscript for important intellectual content. All authors revised and
approved the final version before submission.
Authors information
Professor Sigbjørn Smeland is Head of The Cancer, Surgery and
Transplantation Clinic at Oslo University Hospital which is one of the largest
cancer clinics and cancer research institutes in Europe. Professor Rune
Blomhoff is the Head of The Department of Nutrition at the University of
Oslo, which is the largest nutrition unit in Europe that is associated with a
medical faculty.
Acknowledgements
We thank the participants of the study.
This work was supported by grants from The Norwegian Cancer Society,
Norwegian Research Council and Throne Holst Foundation for Nutrition
Research.
Bøhn et al. BMC Cancer 2012, 12:426 Page 8 of 10
http://www.biomedcentral.com/1471-2407/12/426
Author details
1Department of Nutrition, Institute of Basic Medical Sciences, University of
Oslo, Oslo 0316, Norway. 2Division of Cancer, Surgery and Transplantation,
Oslo University Hospital, Oslo 0310, Norway. 3Department of Biostatistics,
Institute of Basic Medical Sciences, University of Oslo, Oslo 0316, Norway.
4Norwegian Computing Center, Oslo 0314, Norway. 5Department of
Biochemistry, Institute of Basic Medical Sciences, University of Oslo, Oslo
0316, Norway. 6Department of Clinical Chemistry, Oslo University Hospital,
Ullevål, Oslo 0407, Norway. 7Institute for Clinical Medicine, University of Oslo,
Oslo 0316, Norway.
Received: 19 February 2012 Accepted: 3 September 2012
Published: 25 September 2012
References
1. Barcellos-Hoff MH, Park C, Wright EG: Radiation and the microenvironment -
tumorigenesis and therapy. Nat Rev Cancer 2005, 5:867–875.
2. Sturgis EM, Wei Q, Spitz MR: Descriptive epidemiology and risk factors for
head and neck cancer. Semin Oncol 2004, 31:726–733.
3. Pelucchi C, Gallus S, Garavello W, Bosetti C, La VC: Alcohol and tobacco
use, and cancer risk for upper aerodigestive tract and liver. Eur J Cancer
Prev 2008, 17:340–344.
4. World Cancer Research Fund / American Institute for Cancer Research: Food,
Nutrition, Physical Activity, and the Prevention of Cancer. Washington DC: a
Global Perspective; 2007.
5. Bohn SK, Smeland S, Sakhi AK, Thoresen M, Russnes KM, Tausjo J, Svilaas A,
Svilaas T, Blomhoff R: Post-radiotherapy plasma total glutathione is
associated to outcome in patients with head and neck squamous cell
carcinoma. Cancer Lett 2006, 238:240–247.
6. Sakhi AK, Bohn SK, Smeland S, Thoresen M, Smedshaug GB, Tausjo J, Svilaas
A, Karlsen A, Russnes KM, Svilaas T, et al: Postradiotherapy plasma lutein,
alpha-carotene, and beta-carotene are positively associated with survival
in patients with head and neck squamous cell carcinoma. Nutr Cancer
2010, 62:322–328.
7. Sakhi AK, Russnes KM, Thoresen M, Bastani NE, Karlsen A, Smeland S,
Blomhoff R: Pre-radiotherapy plasma carotenoids and markers of
oxidative stress are associated with survival in head and neck
squamous cell carcinoma patients: a prospective study. BMC Cancer
2009, 9:458.
8. de Nadal E, Ammerer G, Posas F: Controlling gene expression in response
to stress. Nat Rev Genet 2011, 12:833–845.
9. Ogawa K, Murayama S, Mori M: Predicting the tumor response to
radiotherapy using microarray analysis (Review). Oncol Rep 2007, 18:1243–
1248.
10. Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum RR:
STAT1 is overexpressed in tumors selected for radioresistance and
confers protection from radiation in transduced sensitive cells. Proc Natl
Acad Sci USA 2004, 101:1714–1719.
11. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C,
Aach J, Ansorge W, Ball CA, Causton HC, et al: Minimum information about
a microarray experiment (MIAME)-toward standards for microarray data.
Nat Genet 2001, 29:365–371.
12. Ishwaran H, Rao JS, Kogalur UB: BAMarraytrade mark: Java software for
Bayesian analysis of variance for microarray data. BMC Bioinforma 2006,
7:59.
13. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al: Gene set
enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci USA 2005,
102:15545–15550.
14. Bohn SK, Myhrstad MC, Thoresen M, Holden M, Karlsen A, Tunheim SH,
Erlund I, Svendsen M, Seljeflot I, Moskaug JO, et al: Blood cell gene
expression associated with cellular stress defense is modulated by
antioxidant-rich food in a randomised controlled clinical trial of male
smokers. BMC Med 2010, 8:54.
15. Lekstrom-Himes J, Xanthopoulos KG: Biological role of the CCAAT/
enhancer-binding protein family of transcription factors. J Biol Chem
1998, 273:28545–28548.
16. Pandit A, Vadnal J, Houston S, Freeman E, McDonough J: Impaired
regulation of electron transport chain subunit genes by nuclear
respiratory factor 2 in multiple sclerosis. J Neurol Sci 2009, 279:14–20.
17. Matsumura S, Demaria S: Up-regulation of the pro-inflammatory
chemokine CXCL16 is a common response of tumor cells to ionizing
radiation. Radiat Res 2010, 173:418–425.
18. Hong JH, Chiang CS, Sun JR, Withers HR, McBride WH: Induction of c-fos
and junB mRNA following in vivo brain irradiation. Brain Res Mol Brain Res
1997, 48:223–228.
19. Sugimoto K, Maekawa Y, Kitamura A, Nishida J, Koyanagi A, Yagita H, Kojima
H, Chiba S, Shimada M, Yasutomo K: Notch2 signaling is required for
potent antitumor immunity in vivo. J Immunol 2010, 184:4673–4678.
20. Bandres E, Malumbres R, Cubedo E, Honorato B, Zarate R, Labarga A, Gabisu
U, Sola JJ, Garcia-Foncillas J: A gene signature of 8 genes could identify
the risk of recurrence and progression in Dukes' B colon cancer patients.
Oncol Rep 2007, 17:1089–1094.
21. Zhao J, Ni H, Ma Y, Dong L, Dai J, Zhao F, Yan X, Lu B, Xu H, Guo Y: TIP30/
CC3 expression in breast carcinoma: relation to metastasis,
clinicopathologic parameters, and P53 expression. Hum Pathol 2007,
38:293–298.
22. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjanen S, Syrjanen K, Collan
Y, Pyrhonen S: MMP-9 (gelatinase B) expression is associated with
disease-free survival and disease-specific survival in colorectal cancer
patients. Cancer Invest 2010, 28:38–43.
23. Qu Y, Zhang H, Zhao S, Hong J, Tang C: The effect on radioresistance of
manganese superoxide dismutase in nasopharyngeal carcinoma. Oncol
Rep 2010, 23:1005–1011.
24. Fountzilas G, Kalogera-Fountzila A, Lambaki S, Wirtz RM, Nikolaou A,
Karayannopoulou G, Bobos M, Kotoula V, Murray S, Lambropoulos A, et al:
MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with
Response to Concomitant Radiotherapy, Cetuximab, and Weekly
Cisplatin in Patients with Locally Advanced Head and Neck Cancer.
J Oncol 2009, 2009:305908.
25. Talbert PB, Henikoff S: Histone variants–ancient wrap artists of the
epigenome. Nat Rev Mol Cell Biol 2010, 11:264–275.
26. Jeong WS, Jun M, Kong AN: Nrf2: a potential molecular target for cancer
chemoprevention by natural compounds. Antioxid Redox Signal 2006,
8:99–106.
27. Hannani D, Sistigu A, Kepp O, Galluzzi L, Kroemer G, Zitvogel L:
Prerequisites for the antitumor vaccine-like effect of chemotherapy and
radiotherapy. Cancer J 2011, 17:351–358.
28. Lisanti MP, Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Pestell
RG, Howell A, Sotgia F: Accelerated aging in the tumor
microenvironment: connecting aging, inflammation and cancer
metabolism with personalized medicine. Cell Cycle 2011, 10:2059–2063.
29. Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, Shores CG: BIIB021, a
novel Hsp90 inhibitor, sensitizes head and neck squamous cell
carcinoma to radiotherapy. Int J Cancer 2010, 126:1216–1225.
30. Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL:
Glutathione dysregulation and the etiology and progression of human
diseases. Biol Chem 2009, 390:191–214.
31. Hercbergs A, Brok-Simoni F, Holtzman F, Bar-Am J, Leith JT, Brenner HJ:
Erythrocyte glutathione and tumour response to chemotherapy.
Lancet 1992, 339:1074–1076.
32. Anasagasti MJ, Martin JJ, Mendoza L, Obrador E, Estrela JM, McCuskey RS,
Vidal-Vanaclocha F: Glutathione protects metastatic melanoma cells
against oxidative stress in the murine hepatic microvasculature.
Hepatology 1998, 27:1249–1256.
33. Semenza GL: Hypoxia-inducible factor 1: oxygen homeostasis and
disease pathophysiology. Trends Mol Med 2001, 7:345–350.
34. Guo G, Yan-Sanders Y, Lyn-Cook BD, Wang T, Tamae D, Ogi J, Khaletskiy A,
Li Z, Weydert C, Longmate JA, et al: Manganese superoxide dismutase-
mediated gene expression in radiation-induced adaptive responses. Mol
Cell Biol 2003, 23:2362–2378.
35. Shimizu T, Iwanaga M, Yasunaga A, Urata Y, Goto S, Shibata S, Kondo T:
Protective role of glutathione synthesis on radiation-induced DNA
damage in rabbit brain. Cell Mol Neurobiol 1998, 18:299–310.
36. Kim SG, Nam SY, Kim CW, Kim JH, Cho CK, Yoo SY: Enhancement of
radiation-inducible hepatic glutathione-S-transferases Ya, Yb1, Yb2, Yc1,
and Yc2 gene expression by oltipraz: possible role in radioprotection.
Mol Pharmacol 1997, 51:225–233.
37. Summers RW, Maves BV, Reeves RD, Arjes LJ, Oberley LW: Irradiation
increases superoxide dismutase in rat intestinal smooth muscle. Free
Radic Biol Med 1989, 6:261–270.
Bøhn et al. BMC Cancer 2012, 12:426 Page 9 of 10
http://www.biomedcentral.com/1471-2407/12/426
38. Oberley LW, St Clair DK, Autor AP, Oberley TD: Increase in manganese
superoxide dismutase activity in the mouse heart after X-irradiation. Arch
Biochem Biophys 1987, 254:69–80.
39. Strongin A, Yovino S, Taylor R, Wolf J, Cullen K, Zimrin A, Strome S, Regine
W, Suntharalingam M: Primary Tumor Volume Is an Important Predictor
of Clinical Outcomes Among Patients With Locally Advanced Squamous
Cell Cancer of the Head and Neck Treated With Definitive
Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012, 82:1823–1830.
doi:10.1186/1471-2407-12-426
Cite this article as: Bøhn et al.: Stress associated gene expression in
blood cells is related to outcome in radiotherapy treated head and neck
cancer patients. BMC Cancer 2012 12:426.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bøhn et al. BMC Cancer 2012, 12:426 Page 10 of 10
http://www.biomedcentral.com/1471-2407/12/426
